ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012
A prospective study of bisphosphonate use and risk of colorectal cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Bisphosphonates and risk of cancers: a systematic review and meta-analysis.British journal of cancer · 2020Pooled it
- Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.British journal of clinical pharmacology · 2013Pooled it
- Oral bisphosphonates and colorectal cancer.Scientific reports · 2017Trial
- Nitrogen-Based Bisphosphonate Use and Risk of Cancer in Women Aged 50 Years and Older: A National Data Linkage Study.International journal of cancer · 2026Article
- Oral Bisphosphonates for Colorectal Cancer Prevention: A Meta-Analytic Reappraisal Beyond Bone Health.Journal of clinical medicine · 2025Review
- The Hub Genes Related to Osteoporosis Were Identified by Bioinformatics Analysis.BioMed research international · 2023Article
- Cholesterol in colorectal cancer: an essential but tumorigenic precursor?Frontiers in oncology · 2023Review
- BCI Suppresses RANKL-Mediated Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss.Frontiers in pharmacology · 2021Article
- Exposure to oral bisphosphonates and risk of gastrointestinal cancer.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020Article
- Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology.NPJ precision oncology · 2017Article
- Prevention of Colorectal Neoplasia.Clinics in colon and rectal surgery · 2016Review
- Oral bisphosphonates and colon cancer: an update.Therapeutic advances in musculoskeletal disease · 2015Review
- Primary prevention of colorectal cancer: myth or reality?World journal of gastroenterology · 2014Review
- Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates.Nature reviews. Clinical oncology · 2013Review
- Exposure to bisphosphonates and risk of colorectal cancer.British journal of clinical pharmacology · 2013Review
- Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2013Article
- Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities.BoneKEy reports · 2013Article
- Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data.BMJ (Clinical research ed.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
purposeBisphosphonates are used for the treatment of bone metastases and have been associated with a lower risk of breast cancer. A recent case-control study showed an inverse association between bisphosphonate use and colorectal cancer. Data from prospective cohorts are lacking. PATIENTS AND
methodsWe prospectively examined the relationship between bisphosphonate use and risk of colorectal cancer among 86,277 women enrolled onto the Nurses Health Study (NHS). Since 1998, participants have returned biennial questionnaires in which they were specifically queried about the regular use of bisphosphonates. We used Cox proportional hazards models to calculate hazard ratios (HRs) and 95% CIs for risk of colorectal cancer.
resultsThrough 2008, we documented 801 cases of colorectal cancer over 814,406 person-years of follow-up. The age-adjusted HR for women who regularly used bisphosphonates was 0.92 (95% CI, 0.73 to 1.14) and was further attenuated after adjustment for other risk factors (multivariate HR, 1.04; 95% CI, 0.82 to 1.33). The risk was not influenced by duration of use (P(trend) = 0.79). Compared with nonusers, the multivariate-adjusted HRs of colorectal cancer were 1.24 (95% CI, 0.94 to 1.64) for women with 1 to 2 years of use, 1.16 (95% CI, 0.79 to 1.69) for 3 to 4 years of use, and 0.97 (95% CI, 0.60 to 1.56) for ≥ 5 years of use. There was no association between bisphosphonate use and colorectal cancer within strata of other risk factors.
conclusionIn a large prospective cohort, we did not observe an association between long-term use of bisphosphonates and risk of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.